The Board of Directors of Zhejiang Orient Gene Biotech Co.,Ltd has authorized a buyback plan on February 7, 2024.
Zhejiang Orient Gene Biotech Co.,Ltd
Equities
688298
CNE100003RM8
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.93 CNY | +4.96% | -0.68% | -21.90% |
12/06 | US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit | MT |
16/05 | Orient Gene Biotech's US Unit Gets FDA Clearance for Fentanyl Detectors | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.90% | 739M | |
-8.90% | 11.53B | |
-12.79% | 7.33B | |
+28.47% | 5.68B | |
-17.87% | 3.71B | |
+7.41% | 2.49B | |
-65.21% | 2.35B | |
+27.85% | 2.23B | |
-11.56% | 2.22B | |
-14.32% | 1.61B |
- Stock Market
- Equities
- 688298 Stock
- News Zhejiang Orient Gene Biotech Co.,Ltd
- Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan.